Cagri Peptide With Retatrutide: UK Evidence, Safety and Availability Bolt Pharmacy Let me introduce you to a NEW peptide : Cagrilintide is an amylin analog which is now being developed in combination with GLP 1 agonist Semaglutide to achieve sustained CagrisSema is a once weekly injection of semaglutide and cagrilintide. Phase 2 clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising Long acting amylin analogues for the management : Current Opinion in Endocrinology, Diabetes & Obesity The Obesity Wars of 2026 continue: Novo's Miss, Lilly's Supremacy, and the Quality of Weight Loss Pivot In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results